CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).

INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40   Alpha Pro Tech, Ltd. (NYSE: APT)...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...

Citius Pharma (CTXR) Corporate Presentation (Jan 2020).

In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic...
video

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below.

https://youtu.be/hnqFdKSG6-A Auris all over the room, even on the ceiling?.
steven boyd, biotech stock review

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

April 2019 Offering On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors...
AR THreats Report, Biotech Stock Reciew

AR Threats Report (CDC)

This report is dedicated to the 48,700 familieswho lose a loved one each year to antibiotic resistanceor Clostridioides difficile, and the...
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...

Latest article

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...